Features

Features

Debates, in-depth articles, and surprising profiles from ASH Clinical News

Show Me the Money? Show Us the Data!

How will NIH’s new requirement that federally funded clinical trials report outcomes affect researchers? The merits and cautions of data sharing have long been a...

Uncommon Presentations, Uncommon Cancers

In this column, Beth Faiman, CNP, PhD, reviews the 5th edition of the Textbook of Uncommon Cancer. Have you read any hematology-related books recently? Let us...

Should Patients With Myelodysplastic Syndromes Undergo Transplant?

For patients with myelodysplastic syndromes (MDS), hematopoietic cell transplantation (HCT) is the only potentially curative option, but the rates of transplant-related morbidity and mortality...

Pulling Back the Curtain: Hetty Carraway, MD, MBA

In this edition, Hetty Carraway, MD, MBA, talks about keeping medicine close to home and the importance of loving what you do. Dr. Carraway...

Agent Orange and Hematologic Malignancies: The Fog of War Still Hovers

More than 40 years after the Vietnam War, the fog of Agent Orange hangs thick over veterans and those providing their medical care. Aging...

Order Matters: The Art and Science of Myeloma Drug Sequencing

Examining the who, what, when, where, and why of myeloma treatment In 1844, Thomas Alexander Bean, one of the first documented patients with multiple myeloma...

Diversity Evolution

The United States is becoming more diverse. Is the medical education system adapting quickly enough? The need for increased diversity in the medical profession is...

Pulling Back the Curtain: Michael Linenberger, MD

What was your first job? I grew up in rural Kansas, so there were plenty of opportunities for employment – most of them were in...

Affordable Care Act: Exit, Stage Right

The rollback of the Affordable Care Act (ACA) is underway. Within hours of taking the oath of office on January 20, President Donald Trump...

Cartwheels for CAR T-Cell Therapy?

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach to targeted immunotherapy to treat cancer, and the details can seem like the stuff...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.